# 4-aminopyridine Treatment for Nerve Injury

> **NCT03701581** · PHASE2,PHASE3 · RECRUITING · sponsor: **John Elfar** · enrollment: 70 (estimated)

## Conditions studied

- Nerve Injury
- Prostate Cancer

## Interventions

- **DRUG:** 4-Aminopyridine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03701581
- **Lead sponsor:** John Elfar
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-05
- **Primary completion:** 2027-07
- **Final completion:** 2028-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03701581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03701581, "4-aminopyridine Treatment for Nerve Injury". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03701581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*